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ELISA	 	 enzyme-linked	immunosorbent	assay	 	
FCS	 	 foetal	calf	serum	 	 	 	 	
GVHD	 	 graft-versus-host	disease	
HAR	 	 hyperacute	rejection	





















































































































































































































































































































































In	 1902,	 Emerich	 Ullman	 performed	 the	 first	 reported	 successful	 experimental	
transplantation	 of	 a	 kidney	 between	 dogs	 (Ullman	 1914).	 The	 graft	 survived	 5	 days.	
Subsequent	 attempted	 xenografts	 proved	 unsuccessful,	 and	 Ullman	 abandoned	 further	
renal	transplant	research.		
In	 1912,	 Alexis	 Carrel,	 ‘the	 father	 of	 transplantation’,	 was	 awarded	 the	 Nobel	 Prize	 in	
Physiology	 or	 Medicine.	 He	 pioneered	 surgical	 techniques,	 particularly	 in	 vascular	
anastomosis	that	are	still	 in	common	practice	today.	He	also	demonstrated	techniques	for	
preserving	 organs	 and	 blood	 vessels	 and	 later	 developed	 an	 early	 perfusion	 pump.	 He	
famously	went	on	to	say	in	1914	“the	technical	problems	of	transplantation	were	essentially	
















During	 the	 Second	World	War,	 a	 zoologist	 named	Peter	Medawar	was	 studying	burn	 and	
wound	healing.	He	recognised	that	skin	grafts	only	worked	when	the	graft	came	from	the	
recipient	 and	 researched	 extensively	 the	 mechanisms	 of	 transplant	 rejection.	 His	 work	
would	represent	the	start	of	an	evolving	area	of	research;	that	of	transplant	immunology.		
In	conjunction	with	Thomas	Gibson,	Medawar	published	a	series	of	papers	on	graft	rejection	
and	 how	 it	 was	mediated	 by	 immune	 cells	 (Gibson	 &	Medawar	 1943),	 (Medawar	 1944).	
They	 demonstrated	 that	 the	 process	 of	 rejection	 in	 both	 human	 and	 rat	 tissue	 was	
characterised	by	 specificity	and	memory	 for	donor	 tissue	and	 that	 it	was	accompanied	by	
infiltration	of	leucocytes.		However,	it	was	an	Australian	virologist,	Frank	Macfarlane	Burnet	








In	 1948,	 Merck	 Company	 produced	 the	 first	 commercially	 available	 adrenal	 cortical	
hormone,	 Cortone	 (cortisone).	 Initially,	 Medawar	 et	 al.	 suggested	 that	 the	
immunosuppressive	 effects	 of	 cortone	 were	 of	 limited	 significant	 benefit.	 	 By	 the	 early	
1950’s,	 a	 number	 of	 groups	 were	 again	 attempting	 human	 kidney	 transplantation.	 The	
surgical	technique	had	by	now	changed	somewhat	and	grafts	were	implanted	into	the	right	
iliac	fossa	with	vascular	anastomosis	to	the	iliac	vessels.	The	results	were	modest	with	grafts	
surviving	 up	 to	 3	 weeks	 on	 the	 immunosuppressive	 regimen	 of	 adrenocorticotrophic	
hormone	(ACTH)	or	cortone.	However	subsequent	studies	by	Medawar	et	al.	demonstrated	
that	 long-term	 graft	 acceptance	 was	 dependent	 upon	 the	 induction	 of	 tolerance.	 It	 was	
generally	 accepted	 that	 the	weak	 steroid	effect	of	 cortone	was	 simply	 insufficient	 and	 its	
use	was	side-lined.		
One	of	the	centres	carrying	out	transplants	in	the	early	1950’s	was	the	Peter	Bent	Brigham	
Hospital	 in	 Boston.	 Here,	 David	 Hume’s	 group	 reported	 on	 a	 series	 of	 nine	 transplants	













into	 his	 twin	 brother,	 who	 was	 suffering	 advanced	 glomerulonephritis.	 The	 recipient	
survived	 for	 eight	 years	 before	 succumbing	 to	 a	 recurrence	 of	 glomerulonephritis	 in	 the	
originally	 unaffected	 kidney.	 This	 success	 provided	 a	 catalyst	 for	 a	 series	 of	 successful	
transplants	 between	 twins	 (Murray,	 Merrill,	 &	 Harrison	 1958)	 and	 highlighted	 several	
important	lessons	on	the	technical	and	ethical	issues,	however	significant	deficiencies	in	the	
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HADC2	 58	 Nucleus	 488	
HDAC3	 50	 Nucleus/Cytoplasm	 428	







HDAC5	 130	 Nucleus/Cytoplasm	 1122	
HDAC7	 110	 Nucleus/Cytoplasm	 855	







HDAC10	 70	 Nucleus/Cytoplasm	 669	
Class	IV	
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Code		 MW	(g.mol-1)		 Range		 Concentration	used	(nM)		
KA001.1		 486.61		 1nM	–	1µM		 1,	10,	100,	1000	
KA005.1		 264.32		 10nM	–	10µM		 10,	100,	1000,	10000	
KA008.6		 540.70		 1nM	–	1µM	 1,	10,	100,	1000	
KA088.2		 515.69		 1nM	–	1µM	 1,	10,	100,	1000	
KA1010		 314.38		 10nM	-10µM		 10,	100,	1000,	10000	
KA146.2		 544.68		 1nM	–	1µM	 1,	10,	100,	1000	
KA147.3		 612.68		 1nM	–	1µM	 1,	10,	100,	1000	
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KA172.1		 547.65		 1nM	–	1µM	 1,	10,	100,	1000	
KA185.1		 546.66		 1nM	–	1µM	 1,	10,	100,	1000	
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62.81	 87.80 47.39	 75.42	 35.17	 64.91	
54.48	 87.17	 39.09	 67.33	 21.68	 42.20	
47.44	 82.67	 38.30	 56.45	 25.61	 37.49	
45.69	 77.00	 33.07	 46.57	 23.82	 32.70	


































	 Stimulator	 Responder	 MLR	 CyA	
A	
Day	0	
	 	 	 	
B	
Day	3	
	 	 	 	
C	
Day	5	




























• SAHA		 –		 0.5µM	or	5µM		










































































































































































































































































































































































































































































































































































































































































































































































































































































































IFN-g	(pg/ml) Reading	1 Reading	2 Abs	
2000 1.868729 2.04204 1.955385
1000 1.125734 1.197155 1.161445
500 0.766742 0.792622 0.779682
250 0.6066 0.52418 0.56539
125 0.438903 0.37193 0.405416
62.5 0.32438 0.339284 0.331832
31.25 0.303043 0.274441 0.288742




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Number		 6		 6		 6		 4		 4		 4		
Duration		 28	days		
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Figure	5-5	Effect	of	KA1010	and	Rapamycin	on	weight	gain	in	mice	undergoing	skin	
grafting	
Treatment	with	the	higher	dose	of	KA1010	(160mg/kg)	long	term	(for	a	period	of	70	days)	
resulted	in	weight	loss	to	approximately	90%	of	original	weight.	A	steady	weight	was	
subsequently	maintained	at	this	level	throughout	the	treatment	period.	However,	data	for	
those	mice	treated	for	a	shorter	period	(28	days)	would	appear	to	contradict	this	as	they	
returned	to	initial	weight	after	10	days.	They	continued	to	gain	weight	steadily	throughout	
the	treatment	period	so	that	by	day	28	they	were	approximately	110%	of	their	initial	body	
weight.	The	reasons	for	this	disparity	are	unexplained.	After	stopping	treatment	with	the	
higher	dose	HDACi,	there	was	a	dramatic	increase	in	weight	gain	such	that	subjects	gained	
approximately	10%	of	body	weight	over	a	very	short	period	of	time	(24-48	hours),	again	the	
reasons	for	this	are	unclear.		
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The	effect	of	treating	mice	with	Rapamycin	had	a	slightly	different	effect	compared	to	
KA1010.	In	those	subjects	treated	with	Rapamycin	alone	(at	a	dose	of	50mg/kg)	steady	
weight	gain	was	observed	throughout	the	treatment	period,	such	that	at	28	days	this	group	
had	a	mean	body	weight	which	was	approximately	10%	greater	than	the	untreated	control	
group.	Interestingly,	when	Rapamycin	(50mg/kg)	was	used	in	combination	with	KA1010	
(80mg/kg)	as	treatment,	the	weight	gain	profile	was	almost	identical	to	that	observed	in	the	
single	agent	KA1010	(80mg/kg)	group.		
	
5.4 Effect	of	KA1010	on	lymphoid	organs	
Calculating	the	splenic	index	is	an	established	method	of	assessing		the	effects	of	a	
compound	on	lymphoid	organs	and	potential	immunotoxicity	(Yu	et	al.	2007).	It	is	calculated	
by	the	following	equation:	
Weight	of	spleen	(mg)	/	body	weight	(g)	
This	results	in	a	relative	index	and	allows	comparisons	to	be	made	between	different	
treatment	groups;	however	detailed	immunotoxic	effects	do	need	to	be	assessed	using	
histopathological	techniques	to	assess	lymphoid	tissue	in	detail.		
Previous	studies	assessing	the	potential	role	of	HDACis	as	an	anti-tumour	agent	in	mouse	
models	of	acute	lymphoblastic	leukaemia	(Einsiedel	et	al.	2006),	found	that	SAHA	reduced	
spleen	weight	non-significantly.	This	data	assesses	the	effects	of	KA1010	and	Rapamycin	on	
the	splenic	index	of	mice	undergoing	allogeneic	skin	transplant.		
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Figure	5-6	Effect	of	KA1010	and	Rapamycin	on	mice	splenic	index.	Treatment	period	is	for	
28	days	unless	stated	(n=8	for	each	group)	
A	normal	splenic	index	would	be	expected	to	be	approximately	3.7	(Grass	et	al.	1999).	In	this	
series,	the	untreated	control	group	had	a	mean	splenic	index	of	3.5	(SEM	0.2,	IQR	3.0-3.9).	
Treatment	with	KA1010	(Figure	5-6)	at	a	dose	of	160mg/kg	for	28	days	resulted	in	a	non-
significant	increase	(unpaired	t-test	p=0.37)	in	splenic	index	to	4.2	(SEM	0.8,	IQR	2.9-5.3).	If	
this	treatment	period	was	extended	to	70	days	(same	dose),	the	splenic	index	fell	back	to	a	
value	of	3.2	(SEM	0.2,	IQR	2.7-3.6).	The	effect	of	reducing	the	dose	of	KA1010	to	80mg/kg	
over	28	days	had	less	of	an	effect	compared	to	the	higher	dose	treatment	with	a	splenic	
index	of	3.2	(SEM	0.5,	IQR	2.5-4.2).	Again	this	dose	was	not	significant	(p=0.43)	when	
compared	to	a	dose	of	160mg/kg.		
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The	effect	of	treatment	with	Rapamycin	in	combination	with	low	dose	KA1010	(80mg/kg)	
for	28	days	resulted	in	the	most	dramatic	change	(though	not	quite	statistically	significant,	
p=	0.08).	Under	these	conditions	a	reduction	in	splenic	index	compared	to	control	was	
observed	with	a	value	of	2.8	(SEM	0.2,	IQR	1.8-3.6).	Treatment	for	28	days	with	Rapamycin	
alone	(50mg/kg)	resulted	in	a	reduction	of	the	splenic	index	to	3.2	(SEM	0.04,	IQR	3.1-3.2).	
This	reduction	was	not	statistically	significant	(p=0.39).	
	
5.5 Effect	of	KA1010	and	Rapamycin	treatment	on	CD4	expression	in	murine	
allogeneic	skin	transplant	model	
To	determine	the	effect	of	HDAC6i	on	the	Treg	population,	the	levels	of	CD4+	T	cells	and	
CD4+FoxP3+	regulatory	T	cells	in	harvested	splenic	tissue	were	compared,	from	treated	and	
untreated	subjects.		
Lymphocytes	were	first	isolated	from	the	splenic	tissue	and	stained	for	CD4+	expression.	The	
proportion	of	CD4+	cells	identified	were	calculated	using	flow	cytometry	(Figure	5-7).		
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Figure	5-7	Example	of	gating	strategy	employed	to	identify	CD4+	T	cells	and	regulatory	
(FoxP3+)	T	cells.	A)	Isolation	of	CD3+	T	cells.	B)	Isolation	of	CD4+	T	cells.	C)	Identification	of	
FoxP3+	T	cells	
Treating	mice	undergoing	skin	transplantation	with	KA1010	(at	a	dose	of	160mg/kg)	for	28	
days	resulted	in	a	non-significant	(p=0.09)	reduction	in	CD4+	expression	from	57.7%	(SEM	
+/-1.9)	to	53.3%	(SEM	+/-1.4)	(Figure	5-8).	If	the	treatment	period	was	extended	to	70	days,	
however,	a	significant	reduction	in	CD4+	T	cells	to	46.9%	of	the	lymphocyte	population	
(p=0.0009)	was	observed.	KA1010	treatment	at	a	dose	of	80mg/kg,	had	a	negligible	effect	
on	CD4+	expression	(reducing	expression	to	55.9%,	SEM	+/-2.4).	However,	treatment	with	
this	dose	in	combination	with	Rapamycin	(50mg/kg)	did	result	in	a	significant	reduction	
C	
A	 B	
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(p=0.003)	in	CD4+	expression	to	48.1%	(+/-1.4).	This	reduction	is	most	likely	due,	primarily	to	
the	effect	of	Rapamycin	in	this	combination,	as	Rapamycin	alone	has	a	similar	effect	(as	
opposed	to	the	negligible	effect	of	KA1010	at	80mg/kg)	in	reducing	CD4+	expression	to	
51.3%	(+/-	0.9,	p=0.01),	though	the	difference	is	not	statistically	significant.		
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Figure	5-8	CD4	expression	following	HDAC6i	and	Rapamycin	treatment.	Treatment	for	28	
days	unless	stated	(n=5	for	each	group)	
	
	
	
	
210	
	
5.6 Effect	of	KA1010	and	Rapamycin	treatment	on	Treg	expression	in	murine	
allogeneic	skin	transplant	model	
The	findings	observed	with	respect	to	CD4+	expression	were	in	general	converse	to	those	
seen	in	terms	of	regulatory	T	cell	expression.		Once	again,	lymphocytes	were	isolated	from	
splenic	tissue	of	mice	undergoing	identical	treatment	conditions.		Positive	selection	of	CD4+	
T	cells	was	undertaken	and	these	cells	were	then	stained	for	FoxP3	transcription	factor	in	
order	to	identify	the	Treg	subpopulation	(Figure	5-7).			
Within	the	untreated	population,	18.5%	(+/-	0.7)	of	the	CD4+	T	cells	expressed	FoxP3	(Figure	
5-9).	Treatment	with	KA1010	(160mg/kg)	resulted	in	a	significant	increase	in	FoxP3	
expression	to	21.2%	(+/-	0.6,	p=0.02).	As	with	CD4+	expression,	the	apparent	effect	of	
KA1010	at	this	dose	over	an	extended	period	(70	days)	was	amplified,	resulting	in	FoxP3	
expression	proportionally	increasing	to	25.7%	(+/-	0.7,	p=0.0002).		
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Figure	5-9	FoxP3	expression	among	the	CD4+	population,	following	HDAC6i	and	Rapamycin	
treatment.	Treatment	for	28	days	unless	stated	(n=5	for	each	group)	
KA1010	at	the	lower	dose	of	80mg/kg	had	no	effect	with	the	total	proportion	of	FoxP3+	cells	
representing	17.7%	(+/-0.9,	p=0.5)	of	the	CD4+	population.	The	addition	of	Rapamycin	
(50mg/kg)	to	this	treatment	regimen	had	little	effect	(17.3%	+/-1.2,	p=0.4).	Treatment	with	
Rapamycin	(50mg/kg)	alone	also	had	a	limited	effect	in	terms	of	FoxP3	expression,	though	
the	mean	expression	was	slightly	greater	than	control	at	20.1%	(+/-2.3,	p=0.4).		
In	order	to	facilitate	comparisons	between	the	effects	of	compounds	on	T	cell	morphology	
the	relative	proportions	of	FoxP3+	cells	to	CD4+	cells	was	calculated	(Figure	5-10).		
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Figure	5-10	Effect	of	treatment	on	proportion	of	Treg:CD4+	T	cells	expression	
By	combining	this	data,	to	compare	the	Teff:Treg	ratio,	it	can	be	concluded	
that	the	most	effective	treatment	regimen,	achieving	the	greatest	proportion	of	Treg	
numbers	was	treatment	with	KA1010	(at	a	dose	of	160mg/kg)	for	a	70	day	period	
(statistically	comparing	treatment	regimens	with	control	using	Dunnets	multiple	comparison	
test	demonstrated	this	as	the	only	significant	regimen	with	p<0.05).	
Published	data	suggests,	the	frequency	of	Tregs	in	lymphoid	tissue	of	C57	strain	mice	of	a	
similar	age	to	be	in	the	vicinity	of	15-20%	(Zhao	et	al.	2007)	and	this	would	be	consistent	
with	the	data	above.	It	has	also	been	shown	that	higher	numbers	of	FoxP3	cells	are	directly	
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proportional	to	improved	graft	outcomes	(Brown	et	al.	2007),	which	would	again	be	
consistent	with	this	data.		
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Chapter	6	
6 Discussion	
The	aim	of	this	study	was	to	assess	the	potential	immunosuppressive	role	of	the	histone	
deacetylase	inhibitor	group	of	compounds	as	pharmaceutical	agents	for	use	in	
transplantation.	In	addition	to	this,	identifying	a	specific	compound	from	this	family,	with	
desirable	characteristics	which	could	be	evaluated	further,	with	the	goal	of	taking	it	forward	
for	additional	development	and	even	clinical	trial	has	also	been	achieved.		
Through	Western	blot	analysis	we	have	identified	the	ubiquitous	presence	of	a	number	of	
HDACs	among	T	cell	sub-populations,	including	HDAC6,	the	specific	target	of	KA1010.	This	is	
consistent	with	other	studies	which	have	demonstrated	the	presence	of	all	eleven	HDACs	in	
resting	T	cells	(Keedy	et	al.	2009).	The	presence	of	HDAC	within	the	CD4+CD25+	subset	can	
be	assumed,	through	multiple	studies	demonstrating	an	effect	of	HDACi	on	FoxP3	
acetylation,	however,	no	evidence	can	be	found	which	has	previously	delineated	this	
specifically	through	Western	blot	protein	analysis.	These	results	partially	address	this	by	
demonstrating	the	presence	of	HDACs	2,	3,	4,	6	and	9	within	this	important	and	relevant	
sub-group.		
One	of	the	major	dose-limiting	factors	of	current	immunosuppression	regimens	relates	to	
off-target	toxicity	profiles,	notably	nephrotoxicity.		Clinically	approved	pan-HDACis	such	as	
SAHA,	are	reasonably	well	tolerated	agents,	with	generally	better	side	effect	profiles	
compared	to	CNIs	(Wagner	et	al.	2010).	They	are	of	course	not	without	some	deleterious	
effects.		
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The	main	application	of	pan-HDAC	inhibitors	to	date	has	been	in	an	oncological	setting,	
where	the	broad	target	profile	and	comparatively	high	dosages	administered	have	been	
generally	accepted,	despite	these	side	effects.	Nausea,	fatigue,	cardiac	conductive	
abnormalities	and	thrombocytopenia	(de	Ruijter	et	al.	2003)	have	all	been	associated	with	
the	clinical	use	of	pan-HDAC	inhibitors	such	as	SAHA	and	sodium	valproate,	though	in	
general	these	effects	have	been	found	to	be	reversible.	It	is	unsurprising	that	given	their	
broad	range	of	targets,	a	wide	and	varied	side	effect	profile	among	different	pan-HDACi	
compounds	occurs.	However,	as	the	availability	of	potential	HDAC-specific	drugs	with	
improved	targeting	increases,	through	engineering	and	continued	discovery	of	naturally	
occurring	compounds,	the	side	effect	profiles	would	also	be	expected	to	lessen.		
Despite	being	a	relatively	recently	discovered	class	of	compounds,	the	side	effect	profiles	of	
pan-HDACis		are	fairly	well	documented,	however	the	toxicity	profiles	of	HDACi	at	a	cellular	
level,	in	general,	are	poorly	understood.	This	may	be	because	their	role	to	date	has	been	
limited	to	the	oncological	environment	and	an	effect	which	may	be	deemed	covetable	in	
this	setting	would	possibly	be	seen	as	detrimental	in	an	alternative	clinical	setting,	such	as	
transplantation,	where	therapeutic	dosages	are	likely	to	be	different.	With	this	in	mind,	we	
undertook	a	cell	viability	assay,	in	order	to	ensure	that	any	potential	compounds	we	took	
further	forward	would	not	have	unacceptable	toxicity	that	would	preclude	them	from	any	
potential	clinical	application.	The	basic	toxicity	studies	undertaken	in	this	study,	assessed	
the	effect	of	treatment	on	PBMCs	and	were	found	to	support	the	theory	that	targeted	HDAC	
inhibition	is	potentially	safer.	In	our	study	we	found	evidence	that	SAHA	causes	greater	
toxicity	at	a	dose	of	2µM	compared	with	HDAC	specific	inhibition	in	the	form	of	KA1010	at	
doses	of	10µM.	
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Once	it	had	been	established	that	HDAC	inhibitors	are	generally	safe	up	to	dosages	in	the	
µM	range	in	vitro,	it	was	then	possible	to	establish	which	agents	from	a	panel	of	both	
traditional	and	novel	compounds	had	potential	immunosuppressive	properties,	through	
simple	proliferation	assays	involving	Jurkat	cells	and	PBMCs.	A	panel	of	ten	HDACi	
compounds	were	supplied	by	Karus.	As	investigators,	in	order	to	reduce	interpretive	bias,	
the	only	information	supplied	at	this	stage	was	the	molecular	weight	and	therapeutic	range	
for	each	compound.		
The	effect	of	HDACi	on	Jurkat	cell	proliferation	was	variable	and	no	consistent	pattern	was	
noted.	Though	this	series	of	experiments	provided	few	conclusions	in	terms	of	proliferative	
effect,	it	did	however	provide	a	degree	of	validation	to	the	toxicity	assays	previously	
undertaken.	A	better	examination	on	the	proliferative	effects	of	HDAC	inhibition	was	
undertaken	using	CFSE-dilution	in	PBMCs.	As	well	as	three	blinded	HDACis,	SAHA,	a	pan-
HDACi	which	has	undergone	the	most	research	in	this	group	of	compounds,	was	taken	
forward	for	further	analysis	and	was	there	on	consistently	utilised	as	a	comparator	
throughout	the	in	vitro	sections	of	this	study.	These	proliferation	studies,	revealed	a	dose-
dependent	inhibitory	effect	of	specific	HDAC	inhibition	superior	to	that	seen	with	SAHA	
(p=0.002,	at	the	lower	dose	of	1nM	this	inhibitory	effect	represented	a	4.7%	and	6.8%	
reduction	over	control	for	SAHA	and	KA1010,	respectively.	At	the	higher	dose	of	1000	nM,	
these	figures	increase	to	9.0%	and	22.6%	respectively).	The	presence	of	IL-2	had	a	minimal	
effect.		Although	no	published	data	exists	to	quantitatively	compare	these	findings	too,	the	
inhibitory	effect	is	consistent	with	a	similar	trend	demonstrated	following	the	treatment	of	
CD4+	T	cells	with	a	comparable	dose	range	of	the	selective-HDACi	(Class	I	&	II),	TSA	(Moreira,	
Scheipers,	&	Sorensen	2003).	It	has	been	postulated	that	this	effect	was	mediated	through	
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suppression	of	NF-κB	protein	and	IL-2	gene	expression	levels	(Licciardi	&	Karagiannis	2012).	
The	possible	cellular	mechanisms	by	which	HDACis	may	exert	their	effect	will	be	discussed	in	
further	detail	later	in	this	chapter.				
In	a	number	of	assays	performed	throughout	this	study,	the	effect	of	supplementing	culture	
media	with	IL-2	was	considered.	IL-2	is	of	course,	a	key	cytokine	in	lymphocyte	physiology,	
particularly	in	T	cell	differentiation	and	Treg	function.	The	rationale	for	supplementing	media	
in	many	of	the	assays	performed	therefore	was	a	concern	that	lack	of	IL-2	might	hamper	a	T-
cell	mediated	response.	In	reality,	very	few	effects	of	IL-2	supplementation	were	noted.					
Harnessing	the	immunomodulatory	functions	of	regulatory	T	cells	is	an	ever	increasing	area	
of	interest	to	many	research	groups.	A	number	of	strategies	have	been	tried	in	order	to	
exploit	the	immunomodulatory	function	of	this	cellular	immune	compartment	by	promoting	
their	function,	expansion,	or	adoptive	transfer.	One	such	strategy	of	particular	relevance	is	
the	effect	of	HDACis	on	Tregs.		
The	potential	role	of	HDACi	therapy	in	FoxP3	homeostasis	has	been	discussed	briefly	in	
chapter	1.	During	the	course	of	this	project,	a	number	of	groups	have	also	studied	this	link	
and	the	body	of	evidence	supporting	a	possible	role	for	HDACis	in	bolstering	the	regulatory	
T	cell	population	as	an	immunotherapy	modality	is	gaining	momentum.	Many	of	these	
studies	were	in	the	context	of	inflammation,	and	the	evidence	for	a	role	in	transplantation	
has	generally	been	limited.		
In	two	murine	models	of	colitis	(one	induced	by	treating	with	dextran	sodium	sulphate	and	
the	other	induced	through	the	adoptive	transfer	of	T	cell	dependent	CD45RBhi),	the	pan-
HDACis	TSA	and	SAHA	were	both	reported	to	have	prevented	the	development	of	colitis	(de	
Zoeten	et	al.	2010;	Tao	et	al.	2007).	However,	when	the	mice	were	treated	with	the	potent	
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class	I	HDACi,	MS275	there	was	no	significant	effect	and	the	subjects	proceeded	to	develop	
worsening	colitis	suggesting	the	protective	effect	of	HADCi	is	not	mediated	by	this	particular	
class.	By	depleting	mice	of	Tregs	or	using	a	strain	of	mice	who	have	a	FoxP3	mutation	(Scurfy	
mice),	the	authors	were	able	to	demonstrate	that	the	favourable	effects	of	the	pan-HDACis	
were	regulatory	T	cell	dependent,	as	these	mice	succumbed	to	colitis	despite	previously	
effective	treatment.		
A	similar	effect	has	subsequently	been	demonstrated	several	times	in	vitro	using	pan-
HDACis	(in	the	nanomolar	range)	in	rhesus	macaque	and	human	regulatory	T	cells	(Akimova	
et	al.	2010;	Johnson	et	al.	2008).	When	HDACis	of	other	structural	class	such	as	the	short	
chain	fatty	acid	(valproic	acid)	have	been	tested	however,	their	effect	on	Treg	function	only	
becomes	apparent	at	the	micro-	to	millimolar	ranges.	Interestingly,	and	of	significant	
relevance	to	this	study,	it	was	also	found	that	the	use	HDACi	compounds	specific	to	class	I	
(such	as	the	benzamides)	had	very	little	effect	on	Treg	function,	even	at	high	dosage,	
suggesting	the	apparent	effect	is	mediated	by	class	II	activity.		
In	this	study,	in	order	to	demonstrate	an	HDACi	effect	of	Tregs	we	adopted	and	modified	an	
assay	based	on	Sakaguchi’s	original	Treg	suppression	experiments.	Following	optimisation	of	
the	assay,	we	were	able	to	demonstrate	the	suppressive	capabilities	of	regulatory	T	cells,	
through	increasing	ratios	of	Tregs	to	effector	T	cells.	The	addition	of	HDACi	(four	compounds	
assessed	–	SAHA,	KA185,	KA142	and	KA1010,	at	nanomolar	concentrations)	resulted	in	a	
modest	though	relevant	inhibition	of	responder	cell	proliferation	from	around	75%	in	the	
control	group	to	86-90%	in	the	treatment	groups	(at	a	Treg	to	responder	ratio	of	1:1).	All	of	
the	HDACis	tested	inhibit	class	II,	supporting	the	notion	that	this	is	a	class-specific	effect	and	
that	the	treatment	of	Tregs	does	indeed	potentiate	their	suppressive	ability.		
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Given	that	HDACi	have	an	apparent	effect	on	regulatory	T	cells,	the	final	experiment	
undertaken	in	this	part	of	the	study	considering	basic	T	cell	physiology,	was	to	consider	the	
impact	on	markers	of	lymphocyte	subsets	(CD3,	CD4,	CD8	and	CD19).	There	is	very	little	
evidence	that	this	effect	of	HDACis	has	been	assessed	previously.	In	our	assessment	of	the	
flow	cytometry	data,	we	found	that	the	pan-HDACi,	SAHA	had	a	profound	dose-dependent	
effect	resulting	in	a	large	increase	in	the	CD4	and	CD19	populations	compared	to	control	
(1078.9%	and	181%	respectively)	and	a	decrease	in	the	CD3	and	CD8	populations	(69.2%	
and	88.5%	respectively),	when	treated	at	a	dose	of	1000µΜ.	The	reasons	for	such	a	sizeable	
shift	in	phenotype	are	unclear,	and	if	these	results	are	not	aberrant,	it	may	be	postulated	
that	the	changes	observed	are	due	to	the	non-specific	nature	of	this	compound	or	a	related	
toxic	effect.	The	effect	of	KA1010	on	lymphocyte	phenotype	was	also	interesting.	At	the	
lower	dose	range	(1-100µΜ)	very	little	effect	was	observed.	However	at	the	higher	dose	(of	
1000µΜ)	there	was	a	subtle	shift	resulting	in	a	reduction	in	CD8	expression	by	17.0%	and	a	
corresponding	increase	in	CD4	expression	by	31.1%.	Unfortunately,	the	CD4	population	was	
not	scrutinised	further,	but	given	that	HDAC6	inhibition	appears	to	enhance	the	Treg	
population,	there	is	a	question	as	to	whether	this	result	may	be	due	to	an	expansion	of	this	
subtype.	
Following	on	from	these	initial	studies	on	the	in	vitro	effects	of	HDACi	on	lymphocyte	
physiology	it	was	concluded,	that	the	agent	with	the	greatest	potential	in	terms	of	
immunosuppressive	effect	was	the	HDAC6i,	KA1010.	In	addition	to	the	evidence	presented	
here,	there	has	been	significant	research	into	both	the	selective	inhibition	(in	terms	of	class	
of	HDAC)	and	specific	inhibition	of	individual	HDACs.	Of	particular	interest,	and	with	
relevance	to	transplantation,	were	findings	reported	by	Professor	Wayne	Hancock’s	
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laboratory	in	Philadelphia.	Here	they	found	that	the	HDAC6	protein	was	expressed	at	levels	
a	number	of	fold	higher	in	Tregs,	compared	to	conventional	T	cells	(de	Zoeten	et	al.	2011).	
Around	the	same	time,	they	were	also	able	to	show	that	treating	mice	with	an	alternative	
HDAC6	inhibitor	doubled	the	expression	of	FoxP3	in	regulatory	T	cells	as	well	as	a	number	of	
Treg	associated	genes	(CTLA-4,	IL-10,	PD-1	and	GITR)	and	down-regulated	IL-2	and	IFN-γ	gene	
expression.	However,	this	effect	was	mediated	by	Tubacin,	a	selective	HDAC6i	with	limited	
clinical	relevance	due	to	its	non-drug-like	structure,	difficult	synthesis	and	high	lipophilicity	
(Butler	et	al.	2010)	making	it	more	a	useful	tool	for	research,	rather	than	an	agent	with	
potential	application	in	transplantation.	As	a	result	however,	the	Tubacin	molecule	has	
undergone	subsequent	bioengineering	and	a	new	HDAC6i,	Tubastatin	A	has	been	developed	
(though	less	selective	for	HDAC6	and	therefore	requires	higher	dosing).	Treatment	of	
murine	Tregs	in	vitro	with	this	drug	also	demonstrated	an	increased	suppressive	activity	of	
Tregs	on	a	T	cell	proliferation	assay.	Similar	assays	using	conventional	T	cell	responders	from	
mice	lacking	HDAC6	(HDAC6	knockout	or	HDAC6-/-	mice)	demonstrated	a	similar	result,	
suggesting	the	effect	was	not	dependent	on	HDAC6	expression	in	T	con	cells.	Tubastatin	A	is	
currently	undergoing	testing	as	a	therapy	for	neurodegenerative	disorders.		
Research	using	HDAC6-/-	mice	has	provided	useful	information	into	the	possible	
mechanisms	by	which	HDAC6i	agents	have	an	immunosuppressive	effect.	These	mice	
undergo	normal	lymphocytic	development	though	do	have	higher	than	normal	levels	of	
hyperacetylated	α-tubulin	in	several	tissue	types	(Zhang	et	al.	2008).	Assessment	of	their	
regulatory	T	cells	reveals	an	effector-memory	phenotype	(TREM,	with	typically	reduced	
expression	of	CD44	and	CD62L	and	increased	CD103	expression).	A	feature	of	TREM	cells,	
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relevant	to	the	transplant	setting,	is	that	they	are	capable	of	activation,	expansion	and	
memory	in	response	to	localised	inflammation	(Kleinewietfeld	et	al.	2005).	
More	recently,	another	selective	HDAC6i,	ACY-738,	has	been	tested	in	NZB/W	mice	in	the	
treatment	of	SLE.	It	was	found	to	increase	the	proportion	of	regulatory	T	cells,	while	also	
alleviating	some	of	the	hallmarks	of	SLE	(unpublished	data).	Further	studies,	using	ACY-738	
in	conjunction	with	a	sirtuin	1	inhibitor,	found	there	was	an	increase	in	the	suppressive	
ability	of	Tregs	(Beier	et	al.		2012).		
Given	our	initial	findings	that	HDACi	are	generally	safer	compounds	with	an	inhibitory	effect	
on	proliferation,	and	the	evidence	above,	KA1010	presented	as	a	viable	agent	to	take	
forward	into	in	vitro	and	in	vivo	models	of	transplantation.	The	first	of	these	undertaken	was	
a	one-way	MLR.	These	assays	were	originally	used	in	order	to	test	HLA	matching	and	assess	
whether	or	not	recipient	lymphocytes	would	react	to	donor	alloantigens.	Though	now	
superseded	by	other	more	technological	methods	clinically,	this	assay	still	provides	a	valid,	if	
not	basic	platform	to	assess	the	effects	of	HDACi	treatment.		
The	first	assay	in	this	series	assessed	the	effect	of	cyclosporin,	SAHA	(pan-HDACi)	and	
KA1010	(HDAC6i)	treatment	on	allogeneic	responders.	We	found	that	at	a	dose	of	200ng/ml	
(equivalent	to	the	standard	clinical	range),	CyA	had	a	moderate	inhibitory	effect	reducing	
proliferation	of	the	parent	population	by	18.5%.	Two	doses	of	the	HDACi	compounds	were	
compared.	At	the	lower	dose	of	0.5μM,	neither	had	a	particularly	marked	effect,	though	
SAHA	treatment	did	result	in	a	statistically	significant	reduction	in	proliferation	of	14%.	At	
the	higher	dose	of	5μM	however,	both	compounds	had	a	marked,	statistically	significant	
effect.	Treatment	with	SAHA	elicited	the	greatest	response	with	a	47%	reduction	in	
proliferation,	however,	as	has	become	increasingly	evident	in	this	study,	the	lack	of	
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specificity	associated	with	this	compound	resulted	in	considerable	toxicity	and	much	of	this	
effect	was	likely	due	to	cell	apoptosis.	Though	the	effect	of	KA1010	treatment	was	not	quite	
as	profound	at	31%	it	was	still	statistically	highly	significant.	Closer	examination	of	the	flow	
cytometry	plots	reveals	further	evidence	of	a	toxic	effect	with	high	dose	pan-HDACi	
treatment.	Analysis	demonstrates	a	living	population	in	the	KA1010	treated	sample	of	65-
70%,	consistent	with	the	control,	as	compared	to	20-25%	cells	surviving	SAHA	treatment.		
In	order	to	confirm	that	the	effect	demonstrated	by	these	compounds	was	indeed	a	
dampening	of	the	alloresponse,	and	that	autologous	effector	cells	were	remaining	largely	
unaffected,	a	novel	‘killing’	assay	was	developed,	based	on	the	one-way	MLR.	This	involved	
culturing	both	autologous	and	allogeneic	targets,	with	the	premise	that	the	allogeneic	
population	would	be	affected	preferentially,	and	the	autologous	population	would	be	
relatively	spared.	Though	the	results	of	this	assay	were	not	as	conclusive	as	hoped,	for	
reasons	that	remain	unclear,	they	do	still	support	the	hypothesis.	Rather	unexpectedly	there	
was	a	significant	lack	of	autologous	survival	over	time,	represented	by	a	precipitous	fall	in	
cell	number.	However	we	were	able	to	demonstrate	that	HDACi	treatment	resulted	in	a	
relative	degree	of	allogeneic	preservation	with	a	3.7-fold	increase	and	4.4-fold	increase	in	
allogeneic	cell	number	over	autologous	(SAHA	and	KA1010	at	a	dose	of	5μΜ	respectively)	at	
72	hours.	The	effect	of	SAHA	toxicity	at	this	dose	was	not	assessed	in	this	assay.		
Despite	the	apparent	shortfalls	of	this	novel	assay,	it	did	provide	valid	data	on	
demonstrating	a	relative	immunosuppressive	effect	by	HDACi	compounds.	No	similar	assay	
has	been	reported	and	the	results	warrant	its	further	development	in	terms	of	
methodology.		
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A	one-way	MLR	essentially	represents	the	recipient	response	to	donor	antigen,	but	does	not	
take	into	account	the	reciprocal	effect	of	recipient	antigen	presentation	(as	in	the	indirect	
pathway).	This	assay	may	be	partially	representative	of	chronic	rejection,	but	of	course	in	
reality,	antigen	presentation	and	recognition	occurs	bilaterally,	particularly	in	the	earlier	
stages	following	allotransplantation.		It	could	be	argued	therefore,	that	an	in	vitro	model	of	
transplantation	is	better	represented	by	a	two-way	MLR.		
Freshly-isolated	PBMCs	from	HLA-mismatched	donors	were	used	and	IFN-γ	release	was	
adopted	as	the	measure	of	alloreactivity	in	this	assay.	This	important	pro-inflammatory	
cytokine	has	a	complex	role	in	the	alloresponse,	usually	in	association	with	other	cytokines	
(IL-1β,	TNFα).	It	is	released	primarily	by	activated	T	cells	and	NK	cells	as	part	of	the	effector	
response	during	allorecognition	and	results	in	induction	of	MHC	expression	in	a	number	of	
tissues.	It	has	both	advantageous	and	disadvantageous	roles	in	the	transplant	setting.	For	
example,	it	has	a	pivotal	role	in	the	cellular	immune	response	by	stimulating	macrophages	
to	produce	further	pro-inflammatory	cytokine	responses.	It	also	upregulates	the	expression	
of	certain	chemokines	and	adhesion	molecules	as	well	as	enhancing	MHC	class	II	antigen	
presentation,	resulting	in	increased	effector	cell	recruitment	(Ferrara	et	al.	2009).	
Conversely,	a	number	of	in	vivo	transplant	models	using	subjects	deficient	in	IFN-γ	
demonstrate	a	protective	role	toward	the	graft.	For	example,	islet	transplants	in	mice	
lacking	IFN-γ	receptors	undergo	a	rapid	rejection	process	(Steiger	et	al.	1998)	which	has	
been	suggested,	is	due	to	the	inhibitory	effect	of	IFN-γ	on	the	proliferation	of	lymphocytes	
and	cytotoxic	T	cell	generation	(Hassan	et	al.	1999;	Konieczny	et	al.	1998).	More	recently,	
evidence	has	emerged	suggesting	IFN-γ	may	have	a	role	in	the	promotion	of		Treg	function	
and	/	or	expansion	(Eljaafari,	Li,	&	Miossec	2009).	These	effects	of	IFN-γ	in	the	setting	of	
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transplantation	extend	beyond	the	scope	of	this	study	and	are	made	even	more	complex	
due	to	altered	roles	in	acute	and	chronic	rejection.	They	do	however	pose	further	questions	
regarding	the	role	of	HDACis	(and	their	effect	on	IFN-γ	production)	and	represent	an	area	
for	further	study.	In	the	context	of	this	study,	IFN-γ	release	provides	a	sensitive	and	reliable	
measure	of	alloreactivity.	
In	a	two-way	MLR,	we	found	that	CyA,	SAHA	and	KA1010	all	had	a	statistically	significant	
dose-dependent	inhibitory	effect.	At	the	lower	dose	range	of	0.3μΜ,	IFN-γ	release	was	
reduced	by	47%,	50%	and	67%	(CyA,	SAHA	and	KA1010	respectively).	At	the	higher	dose	
range	of	1μΜ	the	level	of	inhibition	rose	to	72%,	82%	and	91%	respectively.		
These	findings	are	in	keeping	with	published	data	on	the	effect	of	HDACi	on	IFN-γ,	primarily	
in	autoimmune	disease.	In	one	such	model	of	diabetic	disease	using	rat	islet	cells,	the	effect	
of	treatment	with	SAHA	or	TSA	resulted	in	reduced	IFN-γ	mediated	β-cell	destruction	and	
insulin	production	(Larsen	et	al.	2007).		In	another	model	of	GVHD	in	murine	bone	marrow	
transplantation,	treatment	with	pan-HDACi	suppressed	the	release	of	a	number	of	pro-
inflammatory	cytokines,	including	IFN-γ	(as	well	as	IL-1	and	TNF-α)	(Reddy	et	al.	2008a).	A	
further	study,	using	the	synthetic	pan-HDACi,	ITF2357	at	a	dose	of	25nM,	found	IFN-γ	
release	was	reduced	by	50%	(Leoni	et	al.	2005).		
Current	research	suggests	HDACs	have	a	potential	role	in	transplantation	through	both	the	
innate	and	adaptive	immune	systems.	As	many	of	these	roles	are	HDAC-specific,	it	is	likely	
therefore	that	tailoring	HDAC-specific	inhibitors	to	modify	relevant	pathways	is	not	only	
covetable	but	also	increasingly	plausible	in	the	transplant	setting.		
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For	instance,	HDAC5	has	been	shown	to	be	upregulated	during	the	differentiation	of	
monocytes	to	macrophages	(Baek	et	al.	2009).	HDAC3	has	been	shown	to	negatively	
regulate	myeloid	cell	differentiation	(Ueki,	Zhang,	&	Hayman	2008)	and	the	function	of	
dendritic	cells	and	macrophages	have	been	shown	to	be	influenced	by	the	production	of	
HDAC	regulated	inflammatory	mediators.	
In	general,	the	innate	immune	system	is	primarily	regulated	by	Class	I	HDACs	via	regulation	
of	the	production	of	inflammatory	cytokines.	Class	IIa	HDACs	have	a	pivotal	role	in	the	
adaptive	immune	system,	principally	through	the	regulation	of	T	cell	function.	Interestingly,	
it	is	likely	that	HDAC6	has	a	role	in	both	pathways.	
The	role	of	HDACs	in	innate	immunity	
As	part	of	the	innate	immune	response,	HDACs	have	been	demonstrated	to	have	both	
positive	and	negative	regulatory	effects	over	TLR	pathways.	The	specific	role	of	HDAC	
expression	(and	the	specific	HDACs	involved)	in	encoding	for	pro-inflammatory	cytokines	
such	as	IL6,	IL12,	TNF	and	IFN-β	(Bode	et	al.	2007;	Brogdon	et	al.	2007;	Roger	et	al.	2011)	is	
poorly	understood,	though	it	has	been	suggested	that	deacetylation	of	receptors	in	the	TLR	
pathway	are	inherently	implicated.		
HDACs	may	have	a	positive	effect	on	TLR	signalling	through	the	regulation	of	transcription	
factors,	though	this	is	somewhat	controversial.		In	order	for	TLR-induced	production	of	IFN,	
certain	members	of	the	interferon	regulatory	factor	(IRF)	transcription	factor	family	are	
required	(Gabriele	&	Ozato	2007).	A	number	of	HDACs	have	been	demonstrated	to	be	
involved	in	multiple	cell-specific	TLR	pathways,	a	full	description	of	which	goes	beyond	the	
remit	of	this	thesis.	Of	relevance	however	to	the	allogeneic	response	is	the	TLR-mediated	
recruitment	of	nuclear	factor	kappa-light-chain-enhancer	of	activated	B	cells	(NF-κB)	in	
226	
	
which	it	has	been	shown	(through	HDAC	inhibition)	that	HDACs	have	a	positive	effect	(Bode,		
et	al.	2007;	Roger	et	al.	2011).	However,	this	is	controversial	and	questioned	by	several	
groups.		
It	is	more	likely	that	the	predominant	role	of	HDAC	regulation	in	TLR	pathways	is	a	negative	
one.	Class	I	HDACs	are	most	likely	to	invoke	a	negative	regulatory	response,	through	
histone-dependent	pathways	resulting	in	transcription	factor	suppression.	HDAC1	is	capable	
of	suppressing	inflammatory	gene	promoter	activity	of	several	inflammatory	cytokines	(eg	
IL-12,	COX2	and	IFN-β).	HDAC2	can	impart	a	similar	cytokine	effect	through	the	
sequestration	of	specific	transcriptional	activators	(Shakespear,	Halili,	Irvine,	Fairlie,	&	Sweet	
2011).	HDAC1,	2	and	3	are	also	capable	of	deacetylating	NF-κB	(normally	activated	by	TLR-
ligation)	allowing	the	binding	of	IκBα	(an	inhibitory	subunit)	and	switching	off	NF-κB	
dependent	responses	(Chen	&	Greene	2003).		
The	role	of	HDACis	with	regard	to	interferon	release	is	of	particular	relevance	to	this	study	
and	has	been	mentioned	briefly.	The	exact	mechanism	by	which	Class	I	HDACs	are	involved	
is	not	clearly	understood,	though	in	contrast	to	their	often	transcriptional	regression	role,	it	
would	appear	that	they	are	necessary	for	the	expression	of	IFN-stimulated	genes	(ISGs).	The	
signal	transducer	and	activator	of	transcription	(STAT),	regulates	both	type	I	IFN	signalling	
(IFN-α	and	IFN-β)	and	type	II	(IFN-γ)	which	subsequently	regulates	the	expression	of	ISGs	
(Tang	et	al.	2007).	It	is	likely	that	class	I	HDACs	are	involved	in	the	acetylation	of	STAT	but	
conclusive	evidence	on	their	precise	involvement	remains	elusive.		
In	addition	to	the	role	of	Class	I	HDACs	in	the	innate	pathway,	there	is	also	increasing,	
putative	evidence	of	Class	IIa	involvement	(principally	HDAC7)	though	this	would	appear	to	
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be	a	myeloid-specific	role	in	terms	of	chemokine	regulation	and	unrelated	to	lymphocytes	
(Barneda-Zahonero	et	al.	2013).	
Recent	data	has	implicated	a	possible	role	of	HDAC6	in	the	innate	system	through	the	
regulation	of	macrophage	responses.	Macrophages	are	complex	cells	with	both	anti-
inflammatory	and	pro-inflammatory	roles	depending	upon	their	subtype	(M1	or	M2).	In	a	
study	involving	tubacin	treated	macrophages	stimulated	with	LPS	it	was	found	that	
activation	and	production	of	pro-inflammatory	cytokines	was	significantly	reduced	(Yan	et	
al.	2014).	It	is	likely	that	the	role	of	HDAC6	in	microtubule	acetylation	is	responsible	for	this	
effect.	
The	role	of	HDACs	in	adaptive	immunity	
Class	II	HDACs	have	an	inherent	role	in	the	development	and	function	of	T	cells.		
HDAC7	has	an	important	role	in	cytotoxic	T	lymphocyte	(CTL)	function	through	the	
regulation	of	expression	of	adhesion	molecules,	cytokines	and	cytokine	receptors	(Navarro	
et	al.	2011;	Sweet	et	al.	2012).	In	activated	T	cells,	the	nuclear	export	of	HDAC4	is	critical	in	
the	expression	of	IL-5.		
Of	particular	interest	in	the	context	of	this	study	is	the	role	HDAC9	has	in	Treg	homeostasis	
through	its	interaction	with	FoxP3.	Increased	numbers	of	Tregs	have	been	demonstrated	in	
HDAC9	knockout	mice	(de	Zoeten,	Wang,	Sai,	Dillmann,	&	Hancock	2010).	As	the	results	
described	above	and	others	have	demonstrated,	pan-HDAC	inhibition	results	in	increased	
numbers	and	function	of	Tregs	and	this	effect,	at	least	in	part,	may	well	be	due	to	an	
inhibitory	effect	on	HDAC9.	Unfortunately	however,	the	clinical	manipulation	of	this	
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mechanism	is	likely	to	remain	elusive	due	to	a	current	lack	of	HDAC9-specific	inhibitor	
molecule.		
Pivotal	to	this	study	is	the	role	of	HDAC6	and	its	effect	on	Tregs.	The	exact	mechanism	by	
which	HDAC6	inhibition	exerts	an	enhancing	effect	on	Tregs	is	not	well	understood.	It	is	likely	
its	effect	is	not	mediated	through	direct	interaction	with	FoxP3	(as	is	the	case	with	HDAC9),	
but	rather	through	HSP90	and	HSF1	as	part	of	a	multifaceted	deacetylase-dependent	and	
independent	effect	(these	effects	have	been	described	in	the	Introduction).		
In	terms	of	evidence	of	a	deacetylase-dependent	role,	HSP-90	in	Tregs	from	HDAC6-/-	mice	
have	been	shown	to	be	hyperacetylated	and	several	associated	HSF1	regulated	genes	
upregulated	(Hancock	et	al.	2012).	The	same	study	also	demonstrated	that	in	HDAC6-/-	Tregs,	
another	heat-shock	protein,	HSP-70	forms	a	complex	with	FoxP3	(as	a	chaperone	protein)	
which	results	in	increased	Treg	function	and	survival	(Figure	6-1).	In	addition,	they	also	
demonstrated	that	inhibiting	HSP-70	results	in	defective	function	and	reduced	survival	and	
that	upregulating	HSP-70	has	the	opposite	effect	under	cell	stress	conditions.	Further	
evidence	supporting	this	mechanism	of	action	can	be	demonstrated	through	the	effects	of	
HSP90	inhibitors	resulting	in	similar	Treg	effects.		
229	
	
IC50(µM)IC50(µM)HDAC HDAC
HDAC7 0.986
HDAC8 0.363
HDAC9 0.558
HDAC10 0.643
HDAC11 0.584
N
N
N
NH
O
OH
HDAC1 0.356
HDAC2 1.542
HDAC3 0.710
HDAC4 3.072
HDAC5 1.093
HDAC6 0.008
HSP90
HSF1
HSF1
HADC6i	hyperacetylates
HSP90/HSF1	complex	
resulting	in	release	of	
HSF1
HSF1	induces	expression	of	
several	genes	expressing	heat	
shock	elements	(including	
HSP90)
HSP70FoxP3 Acetylation	of	HSP70	
results	in	activation	–
binds	to	FoxP3	as	
chaperone	protein
Stabilises	FoxP3
Increased	Treg	
function	and	
survival
FoxP3 Acetylation	
of	FoxP3
Promotes	DNA	binding	
and	interaction	with	
transcription	factors
Induces	expression	of	
optimal	genes	
associated	with	Treg	
function
Other	genes	functionally	
important	to	Treg	function	
upregulated	(IL-10,	STAT3)
Downregulates several		
proinflammatory cytokines	
(IFγ,	IL17,	IL2)	,	cytokine	
receptors	and	other	genes	
characteristic	of	non-Tregs 	
Figure	6-1	Potential	mechanisms	by	which	HDAC6i	may	potentiate	regulatory	T	cells	
	
We	further	demonstrated	a	predictable,	dose-dependent	effect	of	HDACi	on	the	two-way	
MLR	by	producing	dose	response	curves.	In	this	in	vitro	model	we	found	an	IC50	for	CyA	of	
625nM,	which	was	comparable	to	the	published	data.	The	effect	of	HDACi	treatment	was	
considerably	more	potent	with	an	IC50	of	82nM	and	13nM	for	KA1010	and	SAHA	
respectively.	We	also	assessed	the	specificity	of	these	compounds	by	calculating	the	Hill	
slope	value	for	each	(0.89	for	KA1010,	0.31	for	SAHA	and	0.35	for	CyA).	This	value	is	a	
marker	of	efficiency	in	terms	of	binding	and	almost	certainly	is	a	reflection	of	the	specificity	
of	the	tested	compounds	with	a	more	targeted	effect	of	KA1010.		
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As	has	been	described,	we	have	demonstrated	several	HDACi-mediated	effects	on	cellular	
proliferation.	Therefore,	as	part	of	the	two-way	MLR	we	considered	if	CyA	or	HDACi	altered	
the	expression	of	resting	CD4+	T	cell	activation	markers.	To	achieve	this	we	evaluated	a	
standard	panel	of	surface	markers,	namely	CD69,	CD25	and	HLA-DR.	We	demonstrated	a	
slightly	superior	effect	of	HDACi	over	CyA	in	reducing	CD69	expression.	In	terms	of	CD25	
expression,	all	HDACi	permitted	a	transient	rise	at	day	two	(as	would	be	expected)	with	CyA	
treatment	inhibiting	any	significant	expression	at	all.	None	of	the	compounds	had	any	effect	
on	expression	of	HLA-DR.	These	observations,	particularly	those	seen	in	CD25	expression	
likely	reflect	the	different	mechanisms	of	action	for	CyA	(via	its	effect	on	IL-2)	and	HDACi	
(modulation	of	Tregs).	
The	final	group	of	experiments	presented	here	examine	the	effect	of	KA1010	on	an	in	vivo	
murine	skin	graft	model	of	transplantation.	First	described	by	Medawar	in	1955,	this	highly	
immunogenic	model	provides	a	well	established	platform	with	which	to	assess	the	effect	of	
MHC-disparate	donor	antigen	presentation	on	recipient	T	cell	responses.	The	procedure	
itself	is	relatively	quick	and	straightforward	to	perform	and	is	highly	reproducible.	The	
nature	of	the	model	allows	assessment	at	both	the	macroscopic	level	through	continued	
visual	assessment	and	at	a	histological	level	through	well	characterised	responses.		
In	this	study,	we	found	that	the	untreated	allogeneic	graft	was	macro-	and	microscopically	
rejected	in	7-21	days	while	the	syngeneic	graft	demonstrated	negligible	evidence	of	
rejection	up	to	the	end	of	the	assessed	time	period	(up	to	70	days).	At	a	dose	of	160mg/kg,	
treatment	with	KA1010	resulted	in	graft	survival	of	77%	at	70	days	and	at	the	lower	dose	of	
80mg/kg	graft	survival	of	50%.		
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In	terms	of	systemic	effects,	KA1010	was	generally	well	tolerated.	The	effect	of	sustained	
treatment	(daily	ip	injection	for	70	days)	was	to	prevent	normal	weight	gain	and	maintain	it	
at	around	80%	birth	weight.	However	interpretation	of	this	observation	requires	caution,	as	
mice	treated	with	KA1010	for	a	shorter	period	of	time	(28days)	gained	weight	at	a	rate	
similar	to	control	subjects.	The	reason	for	the	disparity	observed	is	not	easily	explained.	
There	were	no	other	statistically	significant	effects	of	HDACi	treatment	on	weight.	
Rapamycin	(Sirolimus)	is	a	naturally-derived	macrolide	with	both	immunosuppressive	and	
anti-proliferative	effects.	The	initial	enthusiasm	for	rapamycin	as	an	alternative	de	novo	
immunosuppressant	has	waned	over	recent	years	due	to	its	side	effect	profile	and	its	
potential	role	in	transplantation	remains	uncertain.		It	has	been	studied	extensively,	in	
particular	as	a	possible	adjunct	or	even	alternative	to	current	calcineurin-inhibitors	though	
the	potential	advantage	in	terms	of	reduced	nephrotoxicity	and	risk	of	malignancy,	
compared	to	CNIs	have	often	been	offset	by	other	side	effects	such	as	impaired	wound	
healing,	hyperlipidaemia	and	thrombocytopenia.		
Rapamycin	shares	many	structural	similarities	to	Tacrolimus,	but	rather	than	blocking	the	
calcineurin	pathway,	it	inhibits	B	and	T	cell	proliferation	by	blocking	the	cytokine	stimulated	
mTOR	pathway.	Interestingly,	a	number	of	studies	have	demonstrated	a	positive	effect	of	
rapamycin	on	Treg	expansion	(Battaglia,	Stabilini,	&	Tresoldi	2012;	Gao	et	al.	2007;	Segundo	
et	al.	2006).	As	the	potential	effect	of	HDACi	therapy	is	to	mediate	an	immunosuppressive	
effect	through	upregulation	of	regulatory	T	cells,	via	an	alternative	mechanism,	the	
potential	effect	of	combining	these	two	agents,	but	at	lower	dosage	(in	theory	reducing	
potential	side	effects)	was	assessed.		
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In	terms	of	systemic	effects,	Rapamycin	at	a	dose	of	50mg/kg	either	as	a	single	agent	or	in	
combination	with	low	dose	KA1010	had	no	significant	effect	on	weight	or	splenic	index	as	
compared	to	control.	In	order	to	assess	the	potential	in	vivo	effects	of	KA1010	and	
rapamycin,	CD4+	and	CD4+CD25+	expression	was	evaluated.	We	found	that	rapamycin	alone	
resulted	in	a	significant	reduction	in	CD4+	expression	from	57.7%	to	51.3%	(representing	an	
11.1%	reduction),	though	low	dose	KA1010	(80mg/kg)	had	a	negligible	effect.	Rapamycin	
treatment	in	combination	with	low	dose	KA1010	resulted	in	a	slightly	greater	effect	(to	
48.1%)	but	this	apparent	synergistic	effect	was	not	significantly	superior	to	rapamycin	alone.	
The	effect	on	CD4+CD25+	expression	was	essentially	reciprocal,	though	not	significant.	
Rapamycin	treatment	alone	resulted	in	a	marginal	increase	in	expression	from	18.5%	to	
20.1%.	Low	dose	KA1010	and	combination	treatment	had	no	effect.		
The	role	of	rapamycin,	in	conjunction	with	specific	HDAC6i,	requires	further	investigation.	In	
this	study,	we	found	that	rapamycin	treatment	reduced	the	proportion	of	CD4+	T	cells	but	
had	a	minimal	effect	on	Treg	numbers	in	vivo.	Due	to	the	plasticity	between	various	T	cell	
subsets,	there	is	a	differential	response	between	Teff	cells	and	Tregs	to	rapamycin.	These	data	
are	consistent	with	the	previously	published	observations	demonstrating	a	relative	
increased	suppressive	effect	on	effector	T-cells	over	regulatory	populations	(Zeiser	et	al.	
2008),	(Keating	et	al.	2013).		
The	most	significant	effect	on	CD4+	and	CD4+CD25+	expression	resulted	from	KA1010	
treatment	at	a	dose	of	160mg/kg.	Treatment	for	70	days	significantly	impaired	CD4+	
expression	by	16.2%	and	had	a	corresponding	positive	effect	on	CD4+CD25+,	increasing	
expression	by	18.0%.		
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These	observations	support	the	hypothesis	that	KA1010	enhances	the	immunomodulatory	
effect	of	regulatory	T	cells	and	as	a	result	proliferation	of	the	effector	T	cell	population	is	
impaired.		These	findings	are	consistent	with	the	limited	published	data	assessing	HDAC6-
specific	inhibition	(as	already	described	-	HDAC6-/-	knockout	mice	and	in	mice	treated	with	
HDAC6i	in	models	of	inflammation	and	autoimmunity	(Beier	et	al.	2011;	Beier	et	al.	2012;	de	
Zoeten	et	al.	2010).	
	
6.1 Summary	
Enormous	advancements	have	been	made	over	the	last	50	years	in	terms	of	
immunosuppression	and	the	agents	currently	available	today	have	evolved	significantly	
resulting	in	improved	graft	survival.	However	current	immunosuppressive	regimens,	based	
on	the	ELITE-Symphony	study	(Ekberg	et	al.	2007)	are	far	from	perfect	and	little	has	changed	
over	the	last	twenty	years	in	terms	of	side	effects	and	graft	survival	rates.	As	the	evolution	
of	transplantation	continues	and	the	boundaries	of	what	is	possible	are	pushed	further	(for	
example	composite	tissue	transplantation),	it	is	likely	that	newer,	cleaner	and	more	efficient	
immunosuppressants	are	going	to	be	needed	to	keep	pace.	One	such	group	of	compounds	
which	has	shown	potential	in	this	respect	are	the	histone	deacetylase	inhibitors.	Though	
their	clinical	role	has	been	limited	to	haematological	malignancies	at	present,	pre-clinically	
they	have	shown	great	potential	in	the	management	of	a	number	of	other	malignancies	and	
inflammatory	conditions.		
As	a	result	of	this	interest	in	HDACi,	discussions	with	Karus	therapeutics	led	to	the	
development	of	an	academic-industrial	partnership	which	has	resulted	in	this	study.	They	
were	able	to	provide	us	with	a	panel	of	optimised,	novel	engineered	molecules	with	specific	
234	
	
targets,	upon	which	we	were	able	to	perform	a	number	of	step-wise	investigations.	Firstly,	
we	assessed	simple	effect	and	toxicity	at	a	cellular	level	and	considered	mechanistic	
elements	of	an	apparent	inhibitory	function.	We	then	used	robust	in	vitro	models	of	
alloreactivity,	many	of	which	have	been	used	in	the	development	of	current	
immunosuppressants,	and	compared	the	effects	of	our	candidate	novel	compound	with	
appropriate	well	characterised	compounds.	This	revealed	a	potent	and	predictable	
immunomodulatory	effect	for	KA1010	with	apparently	reduced	toxic	effects	compared	to	
less	specific	HDACi.		Finally	we	used	a	murine	model	of	transplantation	to	demonstrate	the	
immunosuppressive	effectiveness	and	tolerability	of	HDAC6i	treatment.	
In	attempting	to	elucidate	a	mechanism	of	action,	we	have	considered	a	number	of	likely	
contributory	factors.	The	likely	mechanism	of	action	of	KA1010	in	terms	of	its	clinical	
application	is	almost	certainly	a	combination	of	both	acetylase	dependent	and	independent	
effects.	In	this	study,	we	found	that	there	was	a	significant	effect	on	the	function	and	
number	of	regulatory	T	cells	and	it	is	likely	this	is	mediated	through	the	HSP90/HSF1	
pathway	described	above.		
Overall,	this	study	adds	weight	to	the	argument	that	HDACi	analogues	have	clinical	utility,	
with	potentially	favourable	toxicity	profiles	compared	with	existing	immunosuppressive	
agents.		The	availability	for	safer	treatment	regimens	has	the	potential	to	enhance	organ	
survival	and	permit	broader	application	of	organ	replacement	for	patients	with	organ	
failure.	
6.2 Limitations	of	the	study	
The	primary	limitations	in	this	study	involved	the	in	vivo	model	used.	There	are	obvious	
limitations	to	this	murine	model	and	translating	the	above	findings	into	the	clinical	setting	is	
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somewhat	limited	by	the	differences	in	human	and	mouse	physiology,	genetics	and	
immunology.	The	graft	itself	is	essentially	non-vascularised	and	therefore,	ischaemia	may	
contribute	significantly	to	the	immune	response.	In	addition	to	this,	as	well	as	tissue-specific	
antigens	the	skin	also	contains	Langerhans	cells	(specific	antigen	presenting	cells	within	the	
skin)	which	may	skew	the	immune	response	by	activating	host	T	cells.	One	further	
consideration	is	graft	size.	It	has	been	suggested	that	larger	grafts	contain	a	larger	number	
of	APCs	and,	therefore,	may	invoke	altered	host	responses	(Sun	et	al.	1996).	However,	
further	detailed	research	comparing	pancreatic	islet,	cardiac	and	skin	transplant	rejection	
found	that	numbers	of	APCs	or	tissue	specific	antigens	had	little	effect	on	the	degree	of	the	
host	T	cell	response.	Rather,	it	has	been	suggested	that	factors	such	as	graft	micro-
environment	and	size	have	more	of	an	important	role	in	rejection	than	number	of	APCs	
(Jones	et	al.	2001).	Therefore,	a	standardised	protocol	was	used	when	grafting	to	ensure	
skin	samples	were	similar	and	minimise	this	potential	factor.		
Further	limitations	of	this	study	concern	the	established	immunosuppressants	used	as	
comparison	to	the	novel	compounds	tested.	Though	CyA	is	a	very	well	characterised	drug,	
its	use	in	modern	immunosuppression	is	dwindling.	In	hindsight	comparing	effects	with	
Tacrolimus	would	have	been	favoured.	Fortunately	both	CyA	and	Tacrolimus	have	similar	
mechanisms	of	action	and	the	findings	therefore	remain	valid.		
Finally,	the	novel	MLR	killing	assay	has	shortcomings	which	we	were	unable	to	overcome.	
For	reasons	unkown,	the	autologous	population	underwent	significant	inhibition	when	it	
would	have	been	expected	to	be	better	preserved.	Fortunately	a	differential	effect	was	
demonstrated.	With	some	modifications	and	assay	development,	this	could	become	a	useful	
tool.		
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6.3 Further	studies		
Throughout	this	study,	the	targeted	inhibition	of	specific	HDACs	has	been	central.	Of	
particular	interest	in	the	context	of	transplantation	is	the	potential	role	of	an	HDAC9i	
molecule.	Internationally,	many	groups	are	focussing	their	efforts	on	harnessing	the	
inhibitory	effects	of	regulatory	T	cells	for	a	number	of	therapeutic	applications.	From	the	
studies	reviewed	here,	the	role	of	HDAC9	(through	HDAC9	knockout	studies)	in	Treg	
regulation	may	be	of	significant	benefit.	Unfortunately,	no	compound	is	yet	available	which	
can	target	HDAC9	specifically.	If	one	were	to	be	developed,	it	may	represent	a	potential	
therapeutic	drug	which	could	be	effective	in	its	own	right	or	in	combination	with	HDAC6	
targeting.	
The	potential	role	of	Rapamycin	has	been	briefly	assessed	in	this	project,	but	was	only	
considered	at	the	in	vivo	stage.	Further	assessment	of	its	potential	use	as	a	combination	
drug	with	HDAC6i	may	reveal	a	possible	novel	role.	
Though	the	skin	graft	model	adopted	for	this	study	was	useful	in	the	initial	assessment	of	
our	novel	compound,	the	next	stage	would	be	to	examine	its	effects	in	a	vascularised	model.	
Previous	studies	have	demonstrated	a	difference	in	rejection	mechanism	between	
vascularised	and	non-vascularised	models,	particularly	in	terms	of	routes	of	migration	of	
donor	dendritic	cells	(in	the	skin	graft	model,	donor	DCs	tend	to	migrate	via	lymphatic	
drainage	before	vascular	connections	have	been	established).	A	large	number	of	
vascularised	graft	models	would	be	appropriate.	In	terms	of	this	project,	a	murine	sub-
capsular	foetal	pancreatic	islets	model	is	planned	as	well	as	a	rat	cardiac	allograft	model.		
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